Background
On May 13, 2004, Warner-Lambert, a division of Pfizer, Inc., entered into an Assurance of Voluntary Compliance/Discontinuance with the Attorneys General of 50 States and the District of Columbia to settle allegations that Warner-Lambert conducted an unlawful marketing campaign for the drug Neurontin® that violated state consumer protection laws. Among other things, the settlement provides for a $21 million Consumer and Prescriber Education grant program to be administered by a Special Committee of state Attorneys General pursuant to an Oregon court order and an Attorney General Memorandum of Understanding.

The Special Committee is comprised of six permanent members: the Attorneys General of Florida, New York, Ohio, Oregon, Texas and Vermont; and two rotating members: currently the Attorneys General of California and North Carolina. The Special Committee has hired the Center for Evidence-based Policy at Oregon Health & Science University, based in Portland, Oregon, to assist in grant administration.

The Attorney General Consumer and Prescriber Education Grant Program will fund programs designed to provide health care professionals and consumers information relating to prescription drugs, including the way in which drugs are marketed